The US FDA (Food and Drug Administration) has expanded their approval of brivaracetam (Briviact, UCB) to now be used as both a monotherapy or adjunctive therapy for pediatric patients, as young as 1 month old, who suffer with partial-onset seizures, meaning that all three brivaracetam therapies (tablets, oral solution, and IV) can be used for treatment. Marketed by UCB, the approval of Briviact marks the first time the IV formulation is available for children, with the medication already approved to treat adults with epilepsy in adults in the United States.

Read more here.

More on: